Next Article in Journal
Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy
Previous Article in Journal
The IDO Metabolic Trap Hypothesis for the Etiology of ME/CFS
Open AccessBrief Report

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin

Department of Cancer Genetics, University Hospital of Montpellier, 34000 Montpellier, France
Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France
Department of Pathology, Centre Jean Perrin, 63000 Clermont-Ferrand, France
Author to whom correspondence should be addressed.
On behalf the SFMPP: French Society of Predictive and Personalized Medicine.
Diagnostics 2019, 9(3), 83;
Received: 15 July 2019 / Revised: 25 July 2019 / Accepted: 25 July 2019 / Published: 26 July 2019
(This article belongs to the Special Issue Next-Generation Sequencing in Tumor Diagnosis and Treatment)
The expanding use of tumor genome analysis by next generation sequencing to drive target therapies has led to increased germline findings in genes predisposing to hereditary cancer. These putative germline findings obtained from theranostic analyses, such as BRCA1/2 gene testing, large panels, whole-exome, or whole-genome sequencing, need to be managed carefully and in an anticipated way with the patient. Before the genetic analysis of a tumor, specific information should be given to patients, who should be aware that the results may have extra-therapeutic medical issues for themselves and relatives. We previously published a list of 36 actionable genes predisposing to cancer for which informing the patient is recommended prior to pangenomic germline analysis because of available screening or preventive strategies. Here, we report clinical practice considerations and schemes for managing germline findings in tumor analyses, including written informed consent and a multidisciplinary approach involving an oncologist, molecular biologist/pathologist, and geneticist in case of germline findings. A somatic result showing a deleterious mutation in a known predisposing gene in a patient who has consented to this purpose should result in referral to a geneticist who is part of the multidisciplinary team. At any time of the somatic analysis process, the patient may have access to a geneticist consultation if additional information is required. This framework will optimally manage both personalized theranostic issues and specific preventive strategies for individuals and relatives; it will also simplify and accelerate the process of genetic testing. View Full-Text
Keywords: somatic analysis; cancer predisposing genes; secondary findings somatic analysis; cancer predisposing genes; secondary findings
Show Figures

Figure 1

MDPI and ACS Style

Pujol, P.; De La Motte Rouge, T.; Penault-Llorca, F. From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin. Diagnostics 2019, 9, 83.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop